AI Engines For more Details: Perplexity Kagi Labs You
Antioxidant Properties: Humic substances contain antioxidant compounds that may help neutralize harmful free radicals in the body, reducing oxidative stress and inflammation. By scavenging free radicals, humic substances may offer protective effects against various chronic diseases associated with oxidative damage, such as cardiovascular disease, neurodegenerative disorders, and certain types of cancer.
Immune Modulation: Some studies suggest that humic substances may possess immunomodulatory properties, meaning they can modulate the activity of the immune system. By regulating immune responses, humic substances may help support immune function and enhance the body's ability to defend against infections, allergies, and autoimmune disorders. However, further research is needed to fully understand the mechanisms underlying these effects and their clinical significance.
Gastrointestinal Health: Humic substances have been investigated for their potential benefits in promoting gastrointestinal health. It is proposed that humic substances may support digestive function, enhance nutrient absorption, and maintain gut microbiota balance. Additionally, some studies suggest that humic substances may have prebiotic properties, stimulating the growth of beneficial bacteria in the gut and contributing to overall gut health.
Detoxification: Humic substances have been proposed to have detoxifying properties, assisting the body in removing toxins, heavy metals, and other harmful substances. By binding to toxins and facilitating their excretion, humic substances may help protect against toxic overload and reduce the risk of toxin-related health conditions. However, more research is needed to evaluate the efficacy of humic substances as detoxifying agents and their potential clinical applications.
Skin Health: Topical applications of humic substances have been explored for their potential benefits in promoting skin health and wound healing. Humic substances may exhibit anti-inflammatory, antimicrobial, and antioxidant properties that could help alleviate skin conditions such as eczema, acne, and dermatitis. Additionally, humic substances may support tissue repair and regeneration, speeding up the healing process of wounds and ulcers.
Anti-inflammatory Effects: Humic substances may exert anti-inflammatory effects by modulating inflammatory pathways and cytokine production. As inflammation plays a role in the pathogenesis of various chronic diseases, including arthritis, asthma, and inflammatory bowel disease, the anti-inflammatory properties of humic substances may have therapeutic potential in managing these conditions. However, more research is needed to elucidate the mechanisms of action and assess their clinical efficacy.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.6 | -2 |
| Acne | 1.3 | 1 | 0.3 |
| ADHD | 2.1 | 1.6 | 0.31 |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
| Allergic Rhinitis (Hay Fever) | 0.5 | 0.6 | -0.2 |
| Allergies | 2.4 | 3.1 | -0.29 |
| Allergy to milk products | 1.6 | 1.1 | 0.45 |
| Alopecia (Hair Loss) | 0.6 | 0.5 | 0.2 |
| Alzheimer's disease | 3.8 | 3.6 | 0.06 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 1.4 | -6 |
| Ankylosing spondylitis | 1.8 | 2.3 | -0.28 |
| Anorexia Nervosa | 0.5 | 1.7 | -2.4 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 1.7 | 2.3 | -0.35 |
| Atherosclerosis | 1.2 | 0.8 | 0.5 |
| Atrial fibrillation | 1.8 | 1.1 | 0.64 |
| Autism | 4.2 | 2.7 | 0.56 |
| Autoimmune Disease | 0.6 | -0.6 | |
| benign prostatic hyperplasia | 0.7 | -0.7 | |
| Biofilm | 0.2 | -0.2 | |
| Bipolar Disorder | 2.1 | 2.1 | 0 |
| Brain Trauma | 1 | 1 | 0 |
| Cancer (General) | 0.5 | 0.7 | -0.4 |
| Carcinoma | 1 | 1.8 | -0.8 |
| Celiac Disease | 1.6 | 2.1 | -0.31 |
| Cerebral Palsy | 1.1 | 1.6 | -0.45 |
| Chronic Fatigue Syndrome | 2.7 | 2.1 | 0.29 |
| Chronic Kidney Disease | 1 | 1.1 | -0.1 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 0.8 | 0.63 |
| Chronic Urticaria (Hives) | 0.6 | 0.2 | 2 |
| Coagulation / Micro clot triggering bacteria | 0.5 | 0.5 | 0 |
| Cognitive Function | 1.8 | 0.5 | 2.6 |
| Colorectal Cancer | 3.7 | 1.9 | 0.95 |
| Constipation | 2.5 | 0.3 | 7.33 |
| Coronary artery disease | 1.1 | 1.4 | -0.27 |
| COVID-19 | 3.7 | 5.8 | -0.57 |
| Crohn's Disease | 2.1 | 3.7 | -0.76 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 0.9 | -0.9 | |
| deep vein thrombosis | 0.7 | 2 | -1.86 |
| Depression | 4 | 3.5 | 0.14 |
| Dermatomyositis | 0.5 | -0.5 | |
| Eczema | 0.3 | 0.2 | 0.5 |
| Endometriosis | 1.7 | 1.4 | 0.21 |
| Eosinophilic Esophagitis | 1.6 | -1.6 | |
| Epilepsy | 1.8 | 1.6 | 0.13 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 0.7 | -0.7 | |
| Functional constipation / chronic idiopathic constipation | 3.9 | 2.6 | 0.5 |
| gallstone disease (gsd) | 1.2 | 1.2 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 1.1 | 0.18 |
| Generalized anxiety disorder | 1.2 | 1.1 | 0.09 |
| Glioblastoma | 0.6 | 0.2 | 2 |
| Gout | 2 | 1.5 | 0.33 |
| Graves' disease | 1.2 | 3.3 | -1.75 |
| Gulf War Syndrome | 0.8 | 0.4 | 1 |
| Halitosis | 0.5 | 1.1 | -1.2 |
| Hashimoto's thyroiditis | 2 | 1.1 | 0.82 |
| Heart Failure | 2.1 | 1.6 | 0.31 |
| hemorrhagic stroke | 0.5 | -0.5 | |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.5 | 0.5 | |
| Hidradenitis Suppurativa | 0.5 | 1.1 | -1.2 |
| High Histamine/low DAO | 0.4 | 0.5 | -0.25 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 0.7 | -0.7 | |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 1.9 | 2.2 | -0.16 |
| Hypothyroidism | 0.2 | 1.1 | -4.5 |
| Hypoxia | 1.4 | 1.4 | |
| IgA nephropathy (IgAN) | 2.2 | 2 | 0.1 |
| Inflammatory Bowel Disease | 2.9 | 3.6 | -0.24 |
| Insomnia | 1.1 | 3.2 | -1.91 |
| Intelligence | 2.7 | 2.7 | |
| Intracranial aneurysms | 1.7 | 0.7 | 1.43 |
| Irritable Bowel Syndrome | 3.1 | 2.9 | 0.07 |
| ischemic stroke | 2.7 | 1.6 | 0.69 |
| Juvenile idiopathic arthritis | 0.5 | -0.5 | |
| Liver Cirrhosis | 1.8 | 2.1 | -0.17 |
| Long COVID | 2.2 | 3 | -0.36 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.1 | 1.2 | -11 |
| Mast Cell Issues / mastitis | 1.5 | 0.5 | 2 |
| ME/CFS with IBS | 0.5 | -0.5 | |
| ME/CFS without IBS | 0.5 | -0.5 | |
| membranous nephropathy | 0.6 | -0.6 | |
| Menopause | 0.2 | 0.9 | -3.5 |
| Metabolic Syndrome | 3.7 | 4.3 | -0.16 |
| Mood Disorders | 4.5 | 4.4 | 0.02 |
| Multiple Sclerosis | 1.8 | 2.3 | -0.28 |
| Multiple system atrophy (MSA) | 0.5 | -0.5 | |
| neuropathic pain | 0.5 | -0.5 | |
| Neuropathy (all types) | 0.5 | 0.5 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.5 | -0.67 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.7 | 2.6 | 0.04 |
| NonCeliac Gluten Sensitivity | 1.2 | 1 | 0.2 |
| Obesity | 3.2 | 4.9 | -0.53 |
| obsessive-compulsive disorder | 2.5 | 1 | 1.5 |
| Osteoarthritis | 0.7 | 2.1 | -2 |
| Osteoporosis | 1 | 1.4 | -0.4 |
| pancreatic cancer | 0.2 | 0.5 | -1.5 |
| Parkinson's Disease | 3.7 | 3.7 | 0 |
| Polycystic ovary syndrome | 3.1 | 3.8 | -0.23 |
| primary biliary cholangitis | 1.2 | -1.2 | |
| Primary sclerosing cholangitis | 0.5 | 1 | -1 |
| Psoriasis | 1.9 | 1.1 | 0.73 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 2.4 | 0.25 |
| Rosacea | 0.5 | 0.5 | 0 |
| Schizophrenia | 2.5 | 2.5 | 0 |
| scoliosis | 0.8 | 0.5 | 0.6 |
| Sjögren syndrome | 1.1 | 1.3 | -0.18 |
| Sleep Apnea | 1.2 | 1 | 0.2 |
| Slow gastric motility / Gastroparesis | 1.6 | 0.6 | 1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 1.1 | -0.57 |
| Stress / posttraumatic stress disorder | 0.5 | 1.6 | -2.2 |
| Systemic Lupus Erythematosus | 2 | 2.5 | -0.25 |
| Tic Disorder | 1.7 | 0.6 | 1.83 |
| Tourette syndrome | 0.7 | -0.7 | |
| Type 1 Diabetes | 3 | 2 | 0.5 |
| Type 2 Diabetes | 3.5 | 4.2 | -0.2 |
| Ulcerative colitis | 3 | 4.2 | -0.4 |
| Unhealthy Ageing | 1.3 | 0.5 | 1.6 |
| Vitiligo | 1.2 | 0.3 | 3 |
